Trial wins and stock surges: Is UTHR the momentum play?

United Therapeutics stock surged over 19% pre-market after announcing its TETON-1 trial for nebulized Tyvaso achieved its primary goal. The study, targeting idiopathic pulmonary fibrosis (IPF), showed a 130.1 mL improvement in forced vital capacity compared to a placebo. The results also indicated a reduced risk of clinical worsening, providing a major boost to the company's lung disease pipeline.